PostEra
YC W20Boston, US · Founded 2019 · Delaware corporation · 40 employees · 6 known investors
Postera uses artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies. The platform combines machine learning, medicinal chemistry, and software engineering to improve the drug development process.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesAI-powered Drug DiscoveryMachine LearningCOVID-19in /postera-ai/@PostEra_AIycombinator.com ↗

Founders & leadership· Y Combinator alumni (W20)
Investors · 6
Competitors · 5
by search overlapDiabetes Prevention Program7 shared keywords
Cowles_Investments_StemCentrx6 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
Prothena6 shared keywordsProthena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins. The company leverages its scientific legacy from Athena Neurosciences and collaborates with academic and industry partners to advance its pipeline of novel therapeutic candidates.
Ideaya Biosciences5 shared keywordsIdeaya Biosciences develops precision medicines and targeted therapies for patients with hard-to-treat cancers and high unmet need. The company focuses on identifying tumor vulnerabilities and designing first-in-class or best-in-class therapies for the patients most likely to benefit.
PatSnap4 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Companies competing with PostEra for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$26.1MraisedJan 2022 · 21 investors · BiotechnologyRule 506(b)
▶$26.1MraisedJan 2022 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew RobinsonExecutive Officer, Director
- Alpha LeeExecutive Officer, Director
- Aaron MorrisExecutive Officer, Director
- Offering amount
- $27.5M
- Amount sold
- $26.1M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- How PostEra designs drugs from codecen.acs.org · 2026
- PostEra Secures $610M in Funding to Revolutionize Drug Discovery with Machine Learning Technology | SignalBasetrysignalbase.com · 2025
- Pfizer extends AI drug discovery pact with PostEra, adding ADCs to dealendpts.com · 2025
- Amgen lines up new AI biotech partner in PostEra – Endpoints Newsendpts.com · 2023
- NIH grants over $500M to create antivirals for future pandemics – Endpoints Newsendpts.com · 2022
- PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH fundingprnewswire.com · 2022
- A new AI startup has emerged, and Pfizer likes what it sees – Endpoints Newsendpts.com · 2022
- PostEra establishes $260M strategic AI Lab partnership with Pfizer and closes $24M in Series A financing - PostErapostera.ai
